Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated  low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.  Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018
ANN ARBOR, Mich., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions in Chicago.
Toggle Summary Esperion to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Toggle Summary Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
ANN ARBOR, Mich., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Toggle Summary Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results
– Phase 3 Program Achieved Safety and Tolerability Objectives – – Bempedoic Acid Achieved Additional 18% to 31% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% to 33% hsCRP Reduction – – 5-Component MACE Events in the Bempedoic Acid Arm were 4.0% as Compared to
Toggle Summary Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid
– Study Met Safety and Tolerability Endpoints in 52-Week Study – – Bempedoic Acid Achieved Additional 18% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% hsCRP Reduction – – 5-Component MACE Events in the Bempedoic Acid Arm were 6.1% as Compared to 8.2% for